Previous 10 | Next 10 |
Image source: The Motley Fool. I-MAB (NASDAQ: IMAB) Q2 2021 Earnings Call Aug 31, 2021 , 7:00 a.m. ET Jielun Zhu -- Director and Chief Financial Officer Continue reading For further details see: I-MAB (IMAB) Q2 2021 Earnings Call Tran...
I-Mab (IMAB) Q2 2021 Earnings Conference Call August 31, 2021, 08:00 AM ET Company Participants Jingwu Zhang Zang - Founder, Chairman and Director Joan Huaqiong Shen - CEO Jielun Zhu - CFO Conference Call Participants Kelly Shi - Jefferies Jennifer Kim - Cantor Fitzgerald Joseph Catanzaro - P...
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021 PR Newswire 13 significant clinical milestones achieved year-to-date, including critical positive data readout events for felzartamab (TJ202/MOR202), lemz...
I-Mab Announces Upcoming Participation at September Conferences PR Newswire SHANGHAI and GAITHERSBURG, Md. , Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development...
I-Mab Announces Establishment of Environmental, Social and Governance Committee PR Newswire I-Mab received highest first-time ESG rating among China -based biotech companies from MSCI New majority independent ESG committee to set overall ESG strategies fo...
I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021 Conference Call Scheduled at 7:00 a.m. ET (Mandarin) and 8:00 a.m. ET (English) PR Newswire SHANGHAI and GAITHERSBURG, Md. ,...
I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19 - Interim analysis showed positive preliminary results for maintaining patients without mechanical ventilation and reducing the mortalit...
San Diego-based Kumquat Biosciences announced a $2 billion agreement with a Lilly subsidiary to discover small-molecule drugs that stimulate tumor-specific immune responses in cancer patients. Sirnaomics, a Maryland-Suzhou RNAi therapeutics company, filed to raise $300 million in a Ho...
I-Mab (NASDAQ:IMAB) announces that the U.S. FDA has cleared the Investigational New Drug (IND) submission for protollin, an investigational drug to treat Alzheimer's disease, enabling a Phase 1 clinical trial to be initiated. Protollin is a new type of immunotherapy aimed at st...
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease PR Newswire Planning underway for a Phase 1 Trial to assess new immunotherapy aimed at stimulating the innate immune system to clear beta amyloid prot...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...